Funding events ending in 2012
Our funding events ending in 2012 are shown below.
-
MRC - Translational Stem Cell Research funding
The Translational Stem Cell Research Committee (TSCRC) has been established to fund investigator-led research proposals that have clear translational goals, and will consider applications from across the UK. The funding mechanism will also provide a platform for partnership funding which will be considered on a case-by-case basis.
-
MRC - Developmental Pathway Funding Scheme/Developmental Clinical Studies
Therapeutics, Devices and Diagnostics Development
The Developmental Pathway Funding Scheme/Developmental Clinical Studies scheme (DPFS/DCS) supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies.The DPFS/DCS scheme combines the previous individual translational funding schemes, permitting a more flexible and integrated approach to the development of new interventions and diagnostics. This scheme forms part of the MRC’s Translational Research Strategy.
-
ERC Proof of Concept Grant
The objective is to provide funds to enable ERC-funded ideas to be brought to a pre-demonstration stage where potential opportunities for exploitation have been identified. PoC funding (up to 150 000 € for 12 months) aims to help ERC grant-holders bridge the gap between their research and the earliest stage of an innovation where a potentially commercial or socially valuable concept needs validation in order to attract the capital necessary for its continued development.
-
MRC - Translational Stem Cell Research funding
The Translational Stem Cell Research Committee (TSCRC) has been established to fund investigator-led research proposals that have clear translational goals, and will consider applications from across the UK. The funding mechanism will also provide a platform for partnership funding which will be considered on a case-by-case basis.
-
Wellcome Trust - Translational Awards
For applied R&D projects that address an unmet need in healthcare. They are open to academic researchers and companies, and can address almost any area of healthcare. Projects covering any aspect of technology development from a range of disciplines - including physical, computational and life sciences - will be considered. Projects must address an unmet need in healthcare or in applied medical research, offer a potential new solution, and have a realistic expectation that the innovation will be developed further by the market.
-
MRC - Developmental Pathway Funding Scheme/Developmental Clinical Studies
Therapeutics, Devices and Diagnostics Development
The Developmental Pathway Funding Scheme/Developmental Clinical Studies scheme (DPFS/DCS) supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies.The DPFS/DCS scheme combines the previous individual translational funding schemes, permitting a more flexible and integrated approach to the development of new interventions and diagnostics. This scheme forms part of the MRC’s Translational Research Strategy.
-
Wellcome Trust - Seeding Drug Discovery
To facilitate early-stage small-molecule drug discovery. The awards help applicants with a potential drug target or new chemistry embark on a programme of compound discovery and/or lead optimisation.
-
BBSRC - Follow-on funding
This funding is for ‘proof of concept’ at the very early stage of turning research outputs into a commercial proposition.
It funds work to convert an idea into a robust business plan where a route to commercialisation is clear, for example a spin-out (seed or venture finance) or licensing opportunity.
-
BBSRC Super Follow on Funding
A small number of larger strategic awards are available called Super follow-on funding grants, from the BBSRC. This is a pilot scheme and there will be 2 calls for applications to Super follow on funds in 2012.
-
ERC Proof of Concept Grant
The objective is to provide funds to enable ERC-funded ideas to be brought to a pre-demonstration stage where potential opportunities for exploitation have been identified. PoC funding (up to 150 000 € for 12 months) aims to help ERC grant-holders bridge the gap between their research and the earliest stage of an innovation where a potentially commercial or socially valuable concept needs validation in order to attract the capital necessary for its continued development.
-
Heart Research - Novel and emerging technologies
Research projects with an emphasis on (1) novel and emerging technologies and (2) their application to cardiovascular disease prevention and/or treatment, which can be expected to benefit patients within a foreseeable timeframe, will be considered. Appropriate approaches include tissue and bioengineering, the development and evaluation of new diagnostic and therapeutic devices, bioimaging, nanotechnology, biomaterials, genomic and proteomic approaches, computational biology and bioinformatics. NET Grants are not appropriate for funding clinical trials.
-
MRC - Developmental Pathway Funding Scheme/Developmental Clinical Studies
Therapeutics, Devices and Diagnostics Development
The Developmental Pathway Funding Scheme/Developmental Clinical Studies scheme (DPFS/DCS) supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies.The DPFS/DCS scheme combines the previous individual translational funding schemes, permitting a more flexible and integrated approach to the development of new interventions and diagnostics. This scheme forms part of the MRC’s Translational Research Strategy.
-
MRC - Translational Stem Cell Research funding
The Translational Stem Cell Research Committee (TSCRC) has been established to fund investigator-led research proposals that have clear translational goals, and will consider applications from across the UK. The funding mechanism will also provide a platform for partnership funding which will be considered on a case-by-case basis.
-
NIHR - The Efficacy and Mechanism Evaluation (EME) programme (with MRC)
EME was created as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is funded by the MRC and managed by the NIHR as the lead organisation for clinical trials and evaluation.
The EME programme is broadly aimed at supporting 'science driven' studies with an expectation of substantial health gain. The clinical studies are likely to be mostly randomised controlled trials but other forms of evaluation appropriate for the intervention under study will also be supported.
The EME programme aims to support excellent clinical science with an ultimate view to improving health or patient care. Its remit includes clinical trials and evaluative studies - in patients - which: Evaluate clinical efficacy of interventions (where proof of concept in humans has already been achieved); add significantly to our understanding of biological or behavioural mechanisms and processes; explore new scientific or clinical principles; include the development or testing of new methodologies.
-
Heart Research - Novel and emerging technologies
Research projects with an emphasis on (1) novel and emerging technologies and (2) their application to cardiovascular disease prevention and/or treatment, which can be expected to benefit patients within a foreseeable timeframe, will be considered. Appropriate approaches include tissue and bioengineering, the development and evaluation of new diagnostic and therapeutic devices, bioimaging, nanotechnology, biomaterials, genomic and proteomic approaches, computational biology and bioinformatics. NET Grants are not appropriate for funding clinical trials.
-
TSB - SMART
Formerly known as Grant for Research and Development, Smart is available to single companies. Three types of grant are available:
- Proof of market grant
- Proof of concept grant
- Development of prototype grant
Pre start-ups, start-ups, and small and medium-sized businesses from all sectors across the UK may apply for the Smart programme.
-
TSB - SMART
Formerly known as Grant for Research and Development, Smart is available to single companies. Three types of grant are available:
- Proof of market grant
- Proof of concept grant
- Development of prototype grant
Pre start-ups, start-ups, and small and medium-sized businesses from all sectors across the UK may apply for the Smart programme.
-
NIHR - The Efficacy and Mechanism Evaluation (EME) programme (with MRC)
EME was created as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is funded by the MRC and managed by the NIHR as the lead organisation for clinical trials and evaluation.
The EME programme is broadly aimed at supporting 'science driven' studies with an expectation of substantial health gain. The clinical studies are likely to be mostly randomised controlled trials but other forms of evaluation appropriate for the intervention under study will also be supported.
The EME programme aims to support excellent clinical science with an ultimate view to improving health or patient care. Its remit includes clinical trials and evaluative studies - in patients - which: Evaluate clinical efficacy of interventions (where proof of concept in humans has already been achieved); add significantly to our understanding of biological or behavioural mechanisms and processes; explore new scientific or clinical principles; include the development or testing of new methodologies.
-
Heart Research - Translational Research grants
Translational research bridges the gap between scientific research and patient care, bringing about clinical benefits in the most efficient way. This may advance current practice or enable innovative discoveries to be efficiently transferred into practical tools to prevent, diagnose and treat human disease.
Translational research is a dynamic and evolving process to continually improve healthcare and should not stop once the technology is at the patient's bedside. It can be thought of as taking a scientific breakthrough from ‘laboratory bench to hospital bedside and back to bench’ to be further improved. For example, it may help to explain why some treatments stop working or why side-effects may occur.
These grants show our commitment to supporting innovative 'bench-to-bedside' research which can improve the health and treatment of patients with cardiovascular disease.
Maximum award: £150,000
Closing date: 1pm, 1 February every year, applications accepted from the beginning of January. -
Wellcome Trust - R&D for Affordable Healthcare in India
The objective of this initiative is to fund translational research projects that will deliver safe and effective healthcare products for India - and potentially other markets - at affordable costs. A key feature of the scheme is that it encourages innovations that bring together researchers from both the public and private sectors to extend access to care to the greatest numbers of beneficiaries, without compromising on quality.
-
TSB - SMART
Formerly known as Grant for Research and Development, Smart is available to single companies. Three types of grant are available:
- Proof of market grant
- Proof of concept grant
- Development of prototype grant
Pre start-ups, start-ups, and small and medium-sized businesses from all sectors across the UK may apply for the Smart programme.
-
TSB - SMART
Formerly known as Grant for Research and Development, Smart is available to single companies. Three types of grant are available:
- Proof of market grant
- Proof of concept grant
- Development of prototype grant
Pre start-ups, start-ups, and small and medium-sized businesses from all sectors across the UK may apply for the Smart programme.